A multicenter prospective study of infections related morbidity and mortality in cirrhosis of liver

详细信息    查看全文

• 作者：Rajiv Baijal (1)
  Deepak Amarapurkar (1) (2)
  H. R. Praveen Kumar (1)
  Sandeep Kulkarni (1)
  Nimish Shah (1)
  Soham Doshi (1)
  Deepak Gupta (1)
  Mayank Jain (3)
  Nikhil Patel (4)
  Praful Kamani (5)
  S. K. Issar (6)
  Mrudul Dharod (2)
  Apoorva Shah (2)
  Madhuri Chandnani (2)
  Sonali Gautam (2)
  
• 关键词：End ; stage liver disease
• 刊名：Indian Journal of Gastroenterology
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：33
• 期：4
• 页码：336-342
• 全文大小：204 KB
• 参考文献：1. Bajaj JS, O'Leary JG, Wong FK, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut. 2012;61:1219-5. CrossRef
  2. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut. 2005;54:718-5. CrossRef
  3. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18:353-. CrossRef
  4. Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246-6. CrossRef
  5. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140-. CrossRef
  6. Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for HCA bacterial infections. Clin Gastroenterol Hepatol. 2010;8:979-5. CrossRef
  7. Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551-1. CrossRef
  8. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Georges L. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clini Infect Dis. 1998;26:1066-0. CrossRef
  9. Bajaj JS, O’Leary JG, Reddy KR, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56:2328-5. CrossRef
  10. Jain AK, Sircar S, Jain M, Adkar S, Waghmare C, Chahwala F. Acute febrile illness in cirrhosis—thinking beyond spontaneous bacterial peritonitis. Trop Doct. 2012;42:200-.
  11. Mohan P, Ramu B, Bhaskar E, Venkataraman J. Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis. Ann Hepatol. 2011;10:15-0.
  12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-. CrossRef
  13. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-0. CrossRef
  14. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Sem Liver Dis. 1997;17:203-7. CrossRef
  15. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology. 1988;95:1351-.
  16. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310-8.
  17. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72:573-3.
  18. Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269-2. CrossRef
  19. Lo GH, Lai KH, Shen MT, Chang CF. A comparison of the incidence of transient bacteremia and infectious sequelae after sclerotherapy and rubber band ligation of bleeding esophageal varices. Gastrointest Endosc. 1994;40:675-.
  20. Rimola A, Navasa M. Infections in liver disease. / In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, (eds). Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford: Oxford University Press; 1999. pp.1861-4.
  21. Llach J, Elizalde JI, Bordas JM, et al. Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing lower intestinal endoscopy. Gastrointest Endosc. 1999;49:214-7. CrossRef
  22. Sobel JD, Kaye D. Urinary tract infections. / In: Mandell GL, Bennett JE, Dolin R, (eds). Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995. pp. 662-0.
  23. Friedman ND, Kaye KS, Stout JE, et al. Health care associated bloodstream infections in adults: a reason to change the accepted definition of CA infections. Ann Intern Med. 2002;137:791-. CrossRef
  24. Valenti WM, Chiarello LA. Overview of hospital infection control and nosocomial infections. / In: Resse RE, Douglas RG Jr, (eds). A Practical Approach to Infectious Diseases. Boston, MA: Lippincott; 1986. pp. 545-5.
  25. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165-28. CrossRef
  26. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) / Acineto- / bacter baumannii and / Pseudomonas aeruginosa. J Med Microbiol. 2006;55:1619-9. CrossRef
  27. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63:353-5. CrossRef
  28. Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45:223-. CrossRef
  29. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009;50:2022-3. CrossRef
  30. Garcia Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol. 2004;18:353-2. CrossRef
  31. Taneja SK, Dhiman RK. Prevention and management of bacterial infections in cirrhosis. Int J Hepatol. 2011;2011:784540. CrossRef
  32. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27:1207-2. CrossRef
  33. Rongey C, Lim NH, Runyon BA. Cellulitis in patients with cirrhosis and edema: an under-recognized complication currently more common that spontaneous bacterial peritonitis. Open Gastro J. 2008;2:24-. CrossRef
  34. Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2012;49:2087-07. CrossRef
  35. Perez PM, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31:43-. CrossRef
  36. Reiberger T, Ferlitsch A, Payer BA, et al. Nonselective beta-blocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2012;58:911-1. CrossRef
  37. Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38:407-4. CrossRef
  38. Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012;36:866-4. CrossRef
  39. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26-2. CrossRef
  40. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity andmortality in cirrhosis. Am J Gastroenterol. 2007;102:1510-7. CrossRef
  41. Jun DW, Kim KT, Lee OY, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci. 2010;55:1465-1. CrossRef
  
• 作者单位：Rajiv Baijal (1)
  Deepak Amarapurkar (1) (2)
  H. R. Praveen Kumar (1)
  Sandeep Kulkarni (1)
  Nimish Shah (1)
  Soham Doshi (1)
  Deepak Gupta (1)
  Mayank Jain (3)
  Nikhil Patel (4)
  Praful Kamani (5)
  S. K. Issar (6)
  Mrudul Dharod (2)
  Apoorva Shah (2)
  Madhuri Chandnani (2)
  Sonali Gautam (2)
  
  1. Department of Gastroenterology, Jagjivan Ram Hospital, Maratha Mandir Marg, Mumbai Central, Mumbai, 400 008, India
  2. Department of Gastroenterology, Bombay Hospital and Research Centre, 12 Marine Lines, Mumbai, 400 020, India
  3. Department of Gastroenterology, Choitram Hospital and Research Center, Manik Bagh Road, Indore, 452 014, India
  4. Jeevandeep Hospital, 64-B, Opp. Shubhlaxmi Shopping Centre, Station Road, Anand, 388 001, Gujarat, India
  5. Department of Gastroenterology, Wockhardt Hospital, No 2, Parasmani Bunglow, University Road, Panchayat Nagar, Rajkot, 360 005, India
  6. Department of Gastroenterology, Jawaharlal Nehru Hospital and Research Centre, W Hospital Ave, Hospital Sector, Bhilai, Chhattisgarh, 490 009, India
  
• ISSN：0975-0711

文摘

Background and Aims Infections are a common and serious complication among patients with cirrhosis. We assessed the epidemiology, risk factors, and clinical consequences of bacterial infections in cirrhotic patients. Methods In this multicenter prospective study, all patients with cirrhosis of liver with different infections were analyzed. Infections were classified as community-acquired (CA), healthcare-associated (HCA), or hospital-acquired (HA). Site of infection and characteristics of bacteria were recorded; effect on liver function and 30-day survival were evaluated. Results One hundred and six out of 420 (25?%) patients with cirrhosis of liver had infection. Infection rate among indoor patients was 37.5?% (92/245) and among outdoor patients was 8?% (14/175). Out of 106 patients, CA, HCA, and HA were seen in 19.8?%, 50?%, and 30.2?%, respectively. Spontaneous bacterial peritonitis (31.1?%), urinary tract infections (22.6?%), and pneumonia and cellulitis (11.3?% each) were common infections. Gram-negative bacteria (54?%) were more common than Gram-positive cocci (46?%). Multidrug resistant (MDR) organisms were seen in 41.7?% of patients. Most of the MDR organisms were seen in HCA and HA patients. The degree of liver impairment was significantly more severe in patients with infection. Independent predictor of infection was high Child-Turcott-Pugh (CTP) class (p--.006, Child B vs. A (odds ratio (OR) 3.04 95?% CI--.63 to 5.68) and Child C vs. A (OR 4.17 95?% CI--.12 to 8.19). Overall in-hospital mortality was 7.6?%. Patients with infection had increased mortality at 30-day follow up compared to those without infection (23.5?% vs. 2.2?%; p Conclusions Infections are one of the important causes of morbidity and mortality in patients with cirrhosis of liver. The most frequent infections are HCA and HA. Infection predisposes to deterioration of liver function and increases mortality. Cirrhotic patients should be monitored closely for infections especially those with Child class B and C.